• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The invention provides bacterial artificial chromosomes (BACs) comprising retroviral nucleic acid sequences encoding: gag and pol proteins and an env protein or functional substitute thereof, wherein each of the retroviral nucleic acid sequences are arranged as individual expression hybrids within the BAC. The invention also relates to transient transfection uses and methods using said BACs.
    公开号:FR3044017A1
    申请号:FR1661254
    申请日:2016-11-21
    公开日:2017-05-26
    发明作者:Sabine Johnson；Celeste Pallant；Eirini Vamva；Conrad Vink
    申请人:GlaxoSmithKline Intellectual Property Development Ltd；
    IPC主号:
    专利说明:

    FIELD OF THE INVENTION The invention relates to nucleic acid vectors, in particular artificial bacterial chromosomes, comprising genes necessary for retroviral production and their uses. The invention also relates to methods for producing replication defective retroviral vector particles comprising the nucleic acid vectors of the invention.
    BACKGROUND OF THE INVENTION
    In gene therapy, genetic material is administered to endogenous cells in a subject in need of treatment. The genetic material can introduce new genes into the subject or introduce additional copies of preexisting genes, or introduce different alleles or variants of the genes that are present in the subject. Viral vector systems are proposed as a method of efficiently delivering genes for use in gene therapy (Verma and Somia (1997) Nature 389: 239-242).
    In particular, these viral vectors are based on members of the retrovirus family because of their ability to integrate their genetic inheritance into the genome of the host. Retroviral vectors are designed to retain the essential proteins necessary for packaging and distribution of the retroviral genome, but any non-essential accessory protein, including that responsible for their pathogenic profile, is eliminated. Examples of retroviral vectors include lentiviral vectors, such as those based on human immunodeficiency virus type 1 (HIV-1), which are widely used because they are capable of integrating into non-proliferative cells.
    Currently, the majority of viral vectors are produced by transient co-transfection of viral genes into a host cell line. The viral genes are introduced using bacterial plasmids that exist in the host cell only for a limited period of time because the viral genes remain on the plasmids and are not integrated into the genome. As such, transiently transfected genetic material is not passed on to subsequent generations during cell division.
    However, there are many problems associated with current transient transfection methods, such as batch-to-batch variability, the high cost of transfection reagents, and the difficulty of maintaining quality control (see Segura et al., 2013). ) Expert Opin Biol Ther 13 (7): 987-1011). The process of transfection itself also requires many operations and its scaling up is a challenge. It is also difficult to remove the plasmid impurities that are carried during the preparation of the vector (see Pichlmair et al (2007) J. Virol 81 (2): 539-47).
    An object of the present invention is therefore to provide an improved transient transfection method that overcomes one or more of the disadvantages associated with existing methods.
    SUMMARY OF THE INVENTION
    The present inventors have developed a novel mode of producing retroviral vectors which involves the use of nucleic acid vectors comprising a non-mammalian origin of replication and have the capacity to contain at least 25 kilobases (kb) of DNA, such as bacterial artificial chromosomes comprising all of the retroviral genes essential for the production of a retroviral vector. The current transient transfection methods require the use of 3 to 4 separate plasmids carrying the different components required for the production of the retrovirus to be introduced into the host cell, which takes a great deal of time and causes problems related to the pressure of the selection. . The method proposed by the present inventors incorporates all of the essential retroviral genes into a single hybrid that can then be introduced into a host cell, thereby reducing the amount of material needed to transduce the host cell for viral vector production. As a result, it reduces the cost of materials because only one vector is used, unlike earlier methods that utilize multiple plasmid vectors. The use of a nucleic acid vector comprising a non-mammalian origin of replication and having the capacity to contain at least 25 kilobases (kb) of DNA (i.e., a large hybrid DNA) has several advantages . First, the vectors can be first manipulated in non-mammalian cells (eg microbial cells, such as bacterial cells) in contrast to mammalian host cells, which makes them easier to use (eg chromosomes artificial bacterial can be first manipulated in E. coli). Once the nucleic acid vector has been prepared, it can be introduced into a host cell, such as a mammalian host cell, for the production of a retroviral vector. The use of the nucleic acid vectors of the present invention therefore provides advantages in terms of generation of retroviral vectors.
    Therefore, according to a first aspect of the invention, there is provided a bacterial artificial chromosome (BAC) characterized in that said BAC comprises retroviral nucleic acid sequences encoding: gag and pol proteins, and an env protein or a functional substitute thereof wherein each of the retroviral nucleic acid sequences is arranged as individual expression hybrids within the BAC.
    According to another aspect of the invention, the BAC as defined in this specification is proposed for use in a method for producing retroviral vector particles.
    In yet another aspect of the invention there is provided a method for producing a replication defective retroviral vector particle comprising: (a) introducing BAC as defined herein into a host cell culture mammals; and (b) culturing mammalian host cells under conditions to produce the defective retroviral vector particle in replication.
    According to yet another aspect of the invention, there is provided a defective retroviral vector particle in replication obtained by the method as defined in this specification.
    BRIEF DESCRIPTION OF THE FIGURES FIGURE 1: Step by step guide for the construction of BACpack-WTGP-277delU5 and BACpack-SYNGP-277delU5. FIG. 2: Comparison of viral titers obtained in Example 2. 106 HEK293T cells were inoculated in a 6-well plate. The next day, the adhered cells were transfected using PEI according to the manufacturers instructions. The wells were transfected with either a total of 4 μg of wild-type lentivirus (WT) packaging hybrids consisting of pMDL.gp (GagPol), pMD.G (VSVg), pK-Rev (Rev) and pCCL. .277 (GFP transfer vector) either with 2 μg BACpack (a single BAC hybrid containing GagPol, VSVg and Rev) plus 2 μg of the eGFP transfer vector on a separate plasmid. 48 hours after transfection, the supernatant was harvested, filtered through a 0.22 μm filter and stored at -80 ° C for a minimum of 4 hours. HEK293T cells were seeded for transduction at 105 cells per well in a 24-well plate. The next day, the viral supernatant was applied to the cells in serial Polybrene dilutions to a final concentration of 8 μg / ml. 3 days after transduction, the cells were harvested by trypsin treatment and analyzed at the level of GFP by FACS. The viral titer was calculated in transduction units (TU) / ml, calculated according to the following equation: (GFP positive cells / 100) x dilution factor x number of transduced cells.
    Viral titers were compared on the bar chart. All incubations were performed at 37 ° C and 5% CO 2. The media used were DMEM supplemented with 10% FBS and 1 μg / ml doxycycline in the BACpack + transfer sample. FIGURE 3: Transient BACpack transfection into adherent HEK293T cells.
    HEK293T cells were transiently transfected with BACpackWTGP-277delU5, BACpackSYN-277delU5 or the standard 4-plasmid system using the calcium phosphate method. 16 hours after transfection, + Dox conditions were induced for 24 hours with 1 μg / ml of doxycycline. The viral supernatant was harvested 48 hours after transfection, filtered through a 0.22 μτα filter and titrated by transduction of HEK293T cells. GFP-positive transduced cells were used to calculate the transduction units / ml (TU / ml).
    DETAILED DESCRIPTION OF THE INVENTION DEFINITIONS
    Unless otherwise stated, all technical and scientific terms used in this specification have the same meaning as commonly understood by those skilled in the art to which the present invention pertains.
    The term "comprising" includes "including" or "consisting", for example, a composition "comprising" X may consist exclusively of X or may include something more, for example X + Y.
    The term "essentially consisting of" limits the extent of the characteristic to the specified materials or steps and those which do not materially affect the basic characteristics of the claimed feature.
    The term "constituted of" excludes the presence of any additional components.
    The term "about" in relation to a numerical value x means for example x + 1Q%, 5%, 2% or 1%.
    The term "vector" or "nucleic acid vector" refers to a vehicle that is able to artificially carry foreign (ie exogenous) genetic material into another cell, where it can be replicated and / or expressed. Examples of vectors include non-mammalian nucleic acid vectors, such as artificial bacterial chromosomes (BAC), artificial yeast chromosomes (YAC), artificial chromosomes derived from PI (PAC), cosmids or fosmids. Other examples of vectors include viral vectors such as retroviral and lentiviral vectors, which are of particular interest in the present application. Lentiviral vectors, such as those based on the human immunodeficiency virus type 1 (HIV-1), are widely used since they are able to integrate into non-proliferative cells. The viral vectors can be made defective by replication by breaking their viral genome into separate parts, for example by placing it on separate plasmids. For example, what is called the first generation of lentiviral vectors, developed by the Salk Institute for Biological Studies, was constructed as a three-plasmid expression system consisting of an expression cassette. packaging, the envelope expression cassette and the vector expression cassette. The "packaging plasmid" contains all the gag-pol sequences, the regulatory sequences (tat and rev) and accessories (vif, vpr, vpu, nef). The "envelope plasmid" contains the vesicular stomatitis virus glycoprotein (VSVg) in substitution for the native HIV-1 envelope protein, under the control of a cytomegalovirus (CMV) promoter. The third plasmid (the "transfer plasmid") carries the long terminal repeats (LTRs), the encapsulation sequence (ψ), the Rev response element sequence (RRE), and the CMV promoter to express the transgene at the same time. inside the host cell.
    The second generation of lentiviral vectors was characterized by the deletion of virulence sequences vpr, vif, vpu and nef. The packaging vector has been reduced to the gag, pol, tat and rev genes, thereby increasing the safety of the system.
    To improve the lentiviral system, the third-generation vectors were designed by eliminating the tat gene from the packaging hybrid and inactivating the LTRs from the vector cassette, thereby reducing problems with the effects of mutagenesis. insertional.
    The different generations of lentiviruses are described in the following references: First generation: Naldini et al. (1996) Science 272 (5259): 263-7; Second generation: Zufferey et al. (1997) .Nat. Biotechnol. (9): 871-5; Third generation: Dull et al. (1998) J. Vixol, 72 (11): 8463-7. A summary of the development of lentiviral vectors can be found in Sakuma et al. (2012) Biochem. "J. 443 (3): 603-18 and Picanço-Câstro et al. (2008) Exp. Opin. Therap. Patents 18 (5): 525-539.
    The term "non-mammalian origin of replication" refers to a nucleic acid sequence where the replication is initiated and which is derived from a non-mammalian source. This allows the nucleic acid vectors of the invention to stably replicate and segregate alongside endogenous chromosomes in a suitable host cell (e.g., a microbial cell, such as a bacterial or yeast cell) so that to be transmitted alone to the progeny of the host cell unless the host cell is a mammalian host cell. In mammalian host cells, nucleic acid vectors having non-mammalian origins of replication will either be integrated into the endogenous chromosomes of the mammalian host cell, or lost during replication of the mammalian host cell. For example, nucleic acid vectors having non-mammalian origins of replication such as artificial bacterial chromosomes (BAC), artificial chromosome derived from PI (PAC), cosmids or fosmids, are capable of stable replication and segregate with endogenous chromosomes in bacterial cells (such as E. coli), but if they are introduced into mammalian host cells, the BAC, PAC, cosmid or fosmid will either be integrated or lost during replication of the mammalian host cell. Artificial yeast chromosomes (YAC) are able to stably replicate and segregate alongside endogenous chromosomes in yeast cells, but if introduced into mammalian host cells, the YACs will either be integrated or lost during replication of the mammalian host cell. Therefore, in this context, the nucleic acid vectors of the invention act as DNA reservoirs (i.e., for genes essential for retroviral production) that can be easily transferred into mammals to generate retroviral vector particles. Examples of non-mammalian origins of replication include: the origins of bacterial replications, such as oriC, oriV or oriS; the origins of viral replication, such as the SV40 origin of replication; or the origins of yeast replication known as autonomous replication sequences (ARS elements).
    The nucleic acid vectors of the present invention comprise a non-mammalian origin of replication and are capable of containing at least 25 kilobases (kb) of DNA. In one embodiment, the nucleic acid vector has the ability to contain at least 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110 , 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340 or 350 kb d DNA. It is understood that the references to the "capacity to contain" have their usual meaning and imply that the upper limit for the size of the insert for the nucleic acid vector is not less than the claimed size (c '). that is, not less than 25 kb of DNA).
    The object of the present invention is to include genes essential to retroviral packaging in a single hybrid (i.e., the nucleic acid vector). Therefore, the nucleic acid vectors of the invention must be capable of containing large DNA inserts. For the avoidance of doubt, it is understood that references to "nucleic acid vectors" or "artificial chromosomes" do not relate to natural bacterial plasmids (for example as the plasmids currently used in transient transfection methods) because they are not able to contain at least 25 kb of DNA. The maximum size insert that a plasmid can contain is about 15 kb. These nucleic acid vectors also do not refer to bacteriophages, which generally contain only maximal inserts of 5 to 11 kb. Therefore, in one embodiment, the nucleic acid vector of the invention is not a plasmid, nor a bacteriophage, nor an episome.
    The term "endogenous chromosomes" refers to genomic chromosomes in the host cell prior to the generation or introduction of an exogenous nucleic acid vector, such as an artificial bacterial chromosome.
    The terms "transfection," "transformation," and "transduction," as used herein, can be used to describe the insertion of the non-mammalian or viral vector into a target cell. Vector insertion is usually referred to as transformation for bacterial cells and transfection for eukaryotic cells, although insertion of a viral vector may also be termed transduction. Those skilled in the art will be aware of the various non-viral transfection methods commonly used, which include but are not limited to the use of physical methods (e.g. electroporation, cell compression, sonoporation, optical transfection, protoplast fusion, impalfection, magnetofection , gene gun or particle bombardment), chemical reagents (eg calcium phosphate, highly branched organic compounds or cationic polymers) or cationic lipids (eg lipofection). Several transfection methods require the contact of plasmid DNA solutions with the cells that are subsequently cultured.
    The term "promoter" refers to a sequence that drives gene expression. In order to drive a high level of expression, it may be beneficial to use a highly effective promoter, such as a highly effective non-retroviral promoter. Examples of suitable promoters may include a promoter such as the human cytomegalovirus (CMV) immediate early promoter, the spleen focus-forming virus (SFFV) promoter, the Rous sarcoma virus (RSV) promoter or the factor 1 promoter. -alpha of human elongation (pEF).
    The term "polyA signal" refers to a polyadenylation signal sequence, for example in place 3 'of a transgene, which allows host factors to add a polyadenosine tail (polyA) at the end of the nascent mRNA when the transcription. The polyA tail is a stretch of up to 300 adenosine ribonucleotides that protects the mRNA from enzymatic degradation and also facilitates translation. Therefore, the nucleic acid vectors of the present invention may include a polyA signal sequence such as polyA signals of human beta globin or rabbit beta globin, early or late polyA signals of simian virus 40 (SV40), the polyA signal of human insulin, or the polyA signal of bovine growth hormone. In one embodiment, the polyA signal sequence is the polyA signal of human beta globin.
    The term "intron sequence" refers to a nucleotide sequence that is removed from the final gene product by splicing the RNA. The use of an intron downstream of the activator / promoter region and upstream of the cDNA insert has been found to increase the level of gene expression. The increase in expression depends in particular on the cDNA insert. Accordingly, the nucleic acid vector of the present invention may comprise introns such as the intron of human beta globin, intron II of rabbit beta globin, or a chimeric human beta-globin intron. In one embodiment, the intron is an intron of human beta globin and / or an intron II of rabbit beta globin.
    The term "packaging cell line" refers to a cell line that is capable of expressing gag and pol protein and envelope glycoprotein genes. Alternatively, the term "producer cell line" refers to a packaging cell line that is also capable of expressing a transfer vector containing a transgene of interest.
    The term "transiently transfected" refers to transfected cells where target nucleic acids (i.e., retroviral genes) are not permanently incorporated into the cellular genome. Therefore, the effects of the nucleic acids inside the cell only last for a short period of time.
    NUCLEIC ACID VECTORS
    According to one aspect of the invention, there is provided a nucleic acid vector comprising a non-mammalian origin of replication and having the capacity to contain at least 25 kilobases (kb) of DNA, characterized in that said nucleic acid vector comprises retroviral nucleic acid sequences encoding: gag and pol proteins, and an env protein or functional substitute thereof.
    In particular, each of the retroviral nucleic acid sequences may be arranged as individual expression hybrids within the nucleic acid vector.
    The present inventors have found that the nucleic acid vectors described herein can be used to produce retroviral vector particles that eliminate previous difficulties related to retroviral vector production methods. For example, by including all of the essential retroviral genes in the nucleic acid vector, the retroviral genes can then be introduced into a mammalian host cell in a single step. Therefore, the use of a nucleic acid vector, as proposed herein, allows for faster vector production and reduces the amount of material required for the production of retroviral vectors.
    In one embodiment, the nucleic acid vector further comprises nucleic acid sequences that encode the genomic RNA of a retroviral vector particle. It is understood that the genomic RNA of the retroviral vector particle is usually included on the "transfer vector" used in the transient transfection methods. The transfer vector plasmid contains a promoter (such as CMV), the 3 'LTR (which may or may not be a self-activating 3' LTR (ie, SIN), the 5 'LTR (which may contain or not contain the region U5), the encapsidation sequence (ψ) and potentially, the transgene linked to a promoter.
    In one embodiment, multiple copies of the genomic RNA of the retroviral vector particle (i.e., the transfer vector) are included in the nucleic acid vector. Multiple copies of the transfer vector are expected to produce a higher viral vector titer. For example, the nucleic acid vector may comprise two or more copies, such as three, four, five, six, seven, eight, nine or ten or more copies of the genomic RNA of the retroviral vector particle (this is that is, the transfer vector).
    In one embodiment, the nucleic acid vector contains a site or a plurality of recombination sites. The recombinase enzyme catalyzes the recombination reaction between two recombination sites.
    Several types of site specific recombination systems are known in the art and any suitable recombination system can be used in the present invention. For example, in one embodiment, the recombination site (s) are chosen or derived from the lambda phage int / att system, the bacteriophage PI Cre / lox system, the yeast FLP / FRT system, the Gin recombinase system. / gix of Mu phage, Cin recombinase system, E. coli recombinase system Pin and R / RS system of plasmid pSR1, or any combination thereof. In another embodiment, the recombination site is an att site (eg from phage lambda), where the att site allows oriented integration in the presence of lambda integrase. It is understood that the reference to the lambda integrase includes the references to the mutant integrases which are always compatible with the int / att system, for example the modified lambda integrases, described in the document WO 2002/097059.
    In one embodiment, the nucleic acid vector is selected from: an artificial bacterial chromosome (BAC), an artificial yeast chromosome (YAC), an artificial chromosome derived from PI (PAC), a fosmid or a cosmid. In a preferred embodiment, the nucleic acid vector is a bacterial artificial chromosome (BAC).
    Bacterial artificial chromosomes
    According to one aspect of the invention, there is provided a bacterial artificial chromosome (BAC), characterized in that said BAC comprises retroviral nucleic acid sequences encoding: gag and pol proteins, and an env protein or a functional substitute of wherein each of the retroviral nucleic acid sequences is arranged as individual expression hybrids within the BAC.
    The term "artificial bacterial chromosome" or "BAC" refers to a hybrid DNA derived from bacterial plasmids that is capable of containing a large exogenous DNA insert. They can generally contain a maximum DNA insert of about 350 kb. BACs were developed from the well-characterized bacterial functional fertility plasmid (plasmid F) that contains distribution genes that promote regular distribution of plasmids after bacterial cell division. This allows BACs to be stably replicated and segregated alongside endogenous bacterial genomes (such as E. coli). The BAC usually contains at least one copy of an origin of replication (such as the oriS or oriV gene), the repE gene (for plasmid replication and copy number regulation), and distribution genes (such as sopA, sopB , parA, parB and / or parC), which ensures the stable maintenance of the BAC in bacterial cells. BACs are naturally circular and super-coiled, making them easier to recover than linear artificial chromosomes such as YACs. They can also be introduced into bacterial host cells relatively easily, using simple methods such as electroporation.
    In one embodiment, the bacterial artificial chromosome comprises an oriS gene. In one embodiment, the bacterial artificial chromosome comprises a repE gene. In one embodiment, the artificial bacterial chromosome comprises distribution genes. In another embodiment, the distribution genes are selected from sopA, sopB, parA, parB and / or parC. In yet another embodiment, the artificial bacterial chromosome comprises a sopA and sopB gene.
    The BAC for use in the present invention can be obtained from commercial sources, for example the LUCIGEN ™ pSMART BAC (see Genome number EU101022.1 for the complete backbone sequence). This BAC contains the "copy-plus" system of L-arabinose which also contains the copy replication origin of the oriV medium, which is active only in the presence of the TrfA replication protein. The gene for TrfA can be incorporated into the genome of bacterial host cells under the control of the araC-PBAD L-arabinose inducible promoter (see Wild et al (2002) Genome Res., 12 (9): 1434-1444). The addition of L-arabinose induces the expression of TrfA, which activates oriV, which causes plasmid replication of up to 50 copies per cell.
    Artificial chromosomes of yeast
    The term "artificial chromosome of yeast" or "YAC" refers to chromosomes in which the yeast DNA is incorporated into bacterial plasmids. They contain an autonomous replication sequence (ARS) (that is, an origin of replication), a centromere, and telomeres. In contrast to BACs, YAC is linear and therefore contains yeast telomeres at each end of the chromosome to protect its ends from degradation as it is transmitted to the progeny of the host cell. YACs may contain a range of DNA insert sizes, from about 100 to 2000 kb.
    Artificial chromosomes derived from Pl
    The term "artificial chromosome derived from Pl" or "PAC" refers to hybrid DNAs derived from bacteriophage P1 DNA and bacterial F plasmid. They can usually contain a maximum DNA insert of about 100 to 300 kb and are used as cloning vectors in E. coli. PACs have similar benefits to BACs, such as being easily purified and being able to enter bacterial host cells.
    Cosmids and fosmids
    The term "cosmid" refers to hybrid DNAs derived from bacterial plasmids which additionally contain cos sites derived from bacteriophage lambda. Cosmids generally contain an origin of bacterial replication (such as oriV), a selection marker, a cloning site and at least one cos site. Cosmids can usually accept a maximum DNA insert of 40 to 45 kb. Cosmids have been shown to be more effective in the infection of E. coli cells than standard bacterial plasmids. The term "fosmids" refers to non-mammalian nucleic acid vectors that are similar to cosmids except that they are based on bacterial F plasmid. In particular, they use the origin of plasmid F replication and distribution mechanisms that allow the cloning of large fragments of DNA. Fosmids can usually accept a maximum DNA insert of 40 kb.
    RETROVIRUS
    Retroviruses are a family of viruses that contain pseudo-diploid single-stranded genomic RNA. They encode a reverse transcriptase that produces DNA from genomic RNA, which can then be inserted into the DNA of the host cell. The invention described herein can be used to produce replication defective retroviral vector particles. The retroviral vector particle of the present invention may be selected from or derived from any suitable retrovirus.
    In one embodiment, the retroviral vector particle is derived from or selected from a lentivirus, an alpha-retrovirus, a gamma retrovirus, or a foamy retrovirus, such as a lentivirus or a gamma retrovirus, particularly a lentivirus. In another embodiment, the retroviral vector particle is a lentivirus selected from the group consisting of HIV-1, HIV-2, VIS, VIF, VAIE and Visna. Lentiviruses are capable of infecting non-dividing (i.e., quiescent) cells, making them retroviral vectors of interest for gene therapy. In yet another embodiment, the retroviral vector particle is HIV-1 or is derived from HIV-1. The genome structure of some retroviruses may be in the art. For example, details on HIV-1 can be found at GenBank NCBI (Genome Entry # AF033819). HIV-1 is one of the best understood retroviruses and is therefore often used as a retroviral vector. Retroviral genes
    The nucleic acid sequences common to all retroviruses can be further explained as follows: Long terminal repeats (LTRs): The basic structure of a retrovirus genome comprises a 5 'LTR and a 3' LTR between or at within which are located the genes necessary for retroviral production. LTRs are necessary for retroviral integration and transcription. They can also act as promoter sequences to regulate the expression of retroviral genes (which means that they are cis-acting genes). The LTRs are composed of three subregions named U3, R, U5: U3 is derived from the unique sequence at the 3 'end of the RNA, R is derived from a repeat sequence at both ends of the RNA; and U5 is derived from the unique sequence at the 5 'end of the RNA. Therefore, in one embodiment, the nucleic acid vector further comprises a 5 'and 3' LTR. In another embodiment, the U5 region of the 5 'LTR can be deleted and replaced with a non-HIV-1 polyA tail (see Hanawa et al (2002) Mol Ther 5 (3): 242-51). .
    In order to address safety concerns regarding the generation of replication-competent viruses, a self-inactivating vector (SIN) has been developed by deleting a section in the U3 region of the 3 'LTR, which includes the TATA box and binding sites for Spl and NF-κΒ transcription factors (see Miyoshi et al (1998) J. Virol 72 (10): 8150-7). The deletion is transferred to the 5 'LTR after reverse transcription and integration into infected cells, resulting in the transcriptional inactivation of the LTR. This is known as a self-inactivating lentivirus-based vector system that may be included in the present invention. L: Encapsidation of retroviral RNAs occurs by virtue of a ψ (psi) sequence located at the 5 'end of the retroviral genome. It is also well known in the art that sequences downstream of the psi sequence and extending into the gag coding region are involved in the efficient production of retroviral vectors (see Cui et al (1999) J. Virol. (7): 6171-6176). In one embodiment, the nucleic acid vector further comprises a sequence ψ (psi).
    Primer Binding Site (PBS): The retroviral genome contains a PBS that is present after the U5 region of the 5 'LTR. This site binds to the tRNA primer necessary for initiation of reverse transcription. In one embodiment, the nucleic acid vector further comprises a PBS sequence. PPT: Retroviral genomes contain short stretches of purines, called polypurine tract (PPT) near the 3 'end of the retroviral genome. These PPTs serve as RNA primers for DNA synthesis to more strands during reverse transcription. Complex retroviruses (such as HIV-1) contain a second, more centrally located PPT (ie, a central polypurine tract (cPPT)) that provides a second site for initiation of synthesis of the DNA. Retroviral vectors encoding a cPPT have been shown to have enhanced transduction and transgene expression (see Barry et al (2001) Hum Gene Ther 12 (9): 1103-8). In one embodiment, the nucleic acid vector further comprises a 3 'PPT sequence and / or a cPPT sequence.
    The genomic structure of the non-coding regions described above is well known to those skilled in the art. For example, details on the genomic structure of non-coding regions in HIV-1 can be found in the GenBank NCBI database at Genome Entry # AF033819, or for HIV-1 HXB2 (a strain of commonly used HIV-1 reference) at Genome Entry No. K03455. In one embodiment, the non-coding regions are derived from the sequences available under Genome K03455 entry number, e.g. from base pairs 454-1126 (for R-U5-PBS-Gag), 7622- 8479 (for RRE) or 7769-8146 (for RRE), 4781-4898 (for cPPT), 9015-9120 & 9521-9719 (for dNEF-PPT-sinU3-R-U5).
    Gag / pol: The expression of the gag and pol genes is based on a translation shift of the reading frame between gag and gagpol. Both are polyproteins that are cleaved during ripening. The major structural proteins of template, capsid and nucleocapsid of the retroviral vector, are encoded by gag. The pol gene codes for retroviral enzymes: i) reverse transcriptase, essential for the reverse transcription of retroviral genomic RNA into a double-stranded DNA, ii) integrase, which allows the integration of retroviral genomic DNA into a chromosome of the host cell, and iii) protease which cleaves the synthesized polyprotein to produce the mature and functional retrovirus proteins. In one embodiment, the retroviral nucleic acid sequence encoding the gag and pol proteins is derived from the HXB2 sequence of HIV-1, which is available at the Genome KO3455 entry number, for example from bases 790-5105.
    Env: The env ("envelope") gene codes for the surface and transmembrane components of the retroviral envelope (eg glycoproteins gp120 and gp41 of HIV-1) and is involved in membrane fusion of the retroviral cell. In order to broaden tropism of the retroviral vector tissues, the retroviral vectors described herein may be pseudotyped with an envelope protein from another virus. Pseudotyping refers to the method by which the range of host cells of the retroviral vectors, including lentiviral vectors, can be extended or modified by changing the glycoproteins (GPs) on the retroviral vector particles (eg using the obtained or derived GPs). other enveloped viruses or using synthetic / artificial GPs). The glycoprotein most commonly used for pseudotyping retroviral vectors is the vesicular stomatitis virus GP (VSVg), because of its wide tropism and the high stability of its vector particles. However, it is well understood by those skilled in the art that other glycoproteins may be used for pseudotyping (see Cronin et al (2005) Curr, Gene Ther 5 (4): 387-398). The choice of the virus used for the pseudotyping may also depend on the type of cell and / or organ to be targeted because certain pseudotypes have been found to have preferences for a type of tissue.
    In one embodiment, the env protein or a functional substitute thereof is obtained or derived from a virus selected from a vesiculovirus (e.g., vesicular stomatitis virus), a lyssavirus (e.g., rabies virus, Mokola), an arenavirus (eg lymphocytic choriomeningitis virus (LCMV)), alphavirus (eg Ross River virus (RRV), Sindbis virus, Semliki forest virus (SFV), encephalitis virus Venezuelan equine), a filovirus (eg Reston Ebola virus, Zaire Ebola virus, Lassa virus), an alpharetrovirus (eg avian leukosis virus (ALV)), a betarovirus (eg retrovirus Jaagsiekte sheep (JSRV)), a gammaretrovirus (eg, Moloney murine leukemia virus (MLV), Gibbon monkey leukemia virus (GALV), feline endogenous retrovirus (RD114)), a deltartrovirus ( for example a human T-lymphotropic virus 1 (HTLV-1)), a spumavirus (e.g. human foam virus), a lentivirus (e.g., Maedi-visna virus (MVV)), a coronavirus (e.g. SARS-coV), a respirovirus (e.g., Sendai virus). respiratory syncytial virus (RSV)), a hepacivirus (eg, hepatitis C virus (HCV)), an influenza virus (eg, influenza A virus) and a nucleopolyhedrovirus (eg, multiple nucleopolyhedrovirus) Autographa californica (AcMNPV)). In another embodiment, the env protein or a functional substitute thereof is obtained or derived from the vesicular stomatitis virus. In this embodiment, the vesicular stomatitis virus glycoprotein (VSVg) protein can be used, which allows the retroviral particles to infect a wider range of host cells and eliminate the chances of recombination to produce wild-type envelope proteins. In another embodiment, the nucleic acid sequence encoding the env protein or a functional substitute thereof is derived from the sequence available in Genome No. J02428.1, for example from base pairs 3071 to 4720.
    The structural genes described herein are common to all retroviruses. Other helper genes can be found in different types of retroviruses. For example, lentiviruses, like HIV-1, contain six other auxiliary genes known as rev, vif, vpu, vpr, nef, and tat. Other retroviruses may have helper genes that are analogous to the genes described herein, but may not always be indicated under the same name as in the literature. References such as Tomonaga and Mikami (1996) J. Gen. Virol. 77 (Pt 8): 1611-1621 describe various retrovirus helper genes.
    Rev: The rev auxiliary gene ("virion regulator") encodes an accessory protein that binds to the Rev response element (RRE) and facilitates the export of retroviral transcripts. The protein product of the gene allows retroviral mRNA fragments containing the Rev response element (RRE) to be exported from the nucleus into the cytoplasm. The RRE sequence is predicted to form a complex folded structure. This particular role of rev reflects a tight coupling of the splicing and nuclear export stages. In one embodiment, the nucleic acid vector comprises an RRE sequence. In another embodiment, the RRE sequence is derived from the HXB2 sequence of HIV-1 which is available at Genome Accession No. K03455, e.g. from base pairs 7622 to 8479 or 7769 to 8146. , especially base pairs 7622 to 8479.
    Rev binds to RRE and facilitates the export of single-spliced viral transcripts (env, alive, vpr and vpu) or unspliced (gag, pol and genomic RNA), thus causing downstream events such as translation and packaging genes (see Suhasini and Reddy (2009) Curr HIV Res.7 (1): 91-100). In one embodiment, the nucleic acid vector further comprises the rev helper gene or a gene analogous thereto (i.e. from other retroviruses or a functionally similar system). The inclusion of the rev gene ensures the efficient export of the retroviral vector genome RNA transcripts from the nucleus to the cytoplasm, particularly if an RRE element is also included in the transcript to be transported. In another embodiment, the rev gene comprises a sequence identity of at least 60%, as at least 70%, with the base pairs 970 to 1320 of the Genome M11840 entry number (c '). i.e. HIV-1 clone 12 cDNA, locus HIVPCV12). In an alternative embodiment, the rev gene comprises a sequence identity of at least 60%, as at least 70%, 80%, 90% or 100% with the base pairs 5970 to 6040 and 8379 to 8653 Genome K03455.1 (ie Human Immunodeficiency Virus type 1, HXB2).
    Auxiliary genes are thought to play a role in retroviral replication and pathogenesis, therefore, several current viral vector production systems do not include some of these genes. The exception is rev which is usually present or a system similar to the rev / RRE system is potentially used. Therefore, in one embodiment, the nucleic acid sequences encoding one or more vpr, vif, vpu, tat, and nef auxiliary genes or helper genes are terminated such that said helper genes are removed from the RNA genomics of the retroviral vector particle or are unable to encode functional helper proteins. In another embodiment, at least two or more auxiliary genes, three or more, four or more, or all of the vpr, vif, vpu, tat, and nef auxiliary genes, or like helper genes are terminated so that said genes auxiliaries are removed from the genomic RNA of the retroviral vector particle or are unable to encode functional helper proteins. Removal of the functional helper gene may not require removal of the entire gene, removal of a portion of the gene or interruption of the gene will be sufficient.
    It is understood that the nucleic acid sequences encoding the replication defective retroviral vector particle may be the same as, or derived from, the retrovirus wild-type genes on which the retroviral vector particle is based, or that the sequences may be versions of genetically modified or otherwise altered sequences present in the wild-type virus. Therefore, retroviral genes incorporated into nucleic acid vectors or genomes of the host cell can also be referred to as codon-optimized versions of the wild type genes.
    ADDITIONAL COMPONENTS
    The nucleic acid vectors of the invention may comprise several additional components. These additional features can be used to help, for example, stabilize transcripts for translation, increase the level of gene expression, and turn on / off gene transcription.
    The retroviral vector particles produced by the invention can be used in gene therapy methods. Therefore, in one embodiment, the nucleic acid vector comprises one or more transgenes. This transgene may be a therapeutically active gene that encodes a gene product that can be used to treat or ameliorate a target disease. The transgene may encode, for example, antisense RNA, a ribozyme, a protein (for example a tumor suppressor protein), a toxin, an antigen (which may be used to induce antibodies or helper T cells or cytotoxic T lymphocytes) or an antibody (such as a single-stranded antibody). In one embodiment the transgene encodes beta globin.
    Multiple copies of the transgene-containing transfer vector are expected to increase the titer of the retroviral vector, therefore, in one embodiment, the nucleic acid vector comprises multiple copies of the transgene, such as two copies. transgene or more, especially three or more. In some cases, more than one gene product is required to treat a disease, therefore, in another embodiment, the nucleic acid vector further comprises two or more different transgenes, such as three or more, or four or more.
    References to a "transgene" refers to heterologous or foreign DNA that is not present or not sufficiently expressed in the host cell of a mammal into which it is introduced. This may include, for example, the case where a target gene is not correctly expressed in the mammalian host cell, therefore a corrected version of the target gene is introduced as a transgene. Therefore, the transgene may be a gene of potential therapeutic interest. The transgene may have been obtained from another cell type, or from another species, or synthetically prepared. Alternatively, the transgene may have been obtained from a host cell, but operably linked to regulatory regions that are different from those present in the native gene. Alternatively, the transgene may have a different allele or variant different from a gene present in the host cell.
    The goal of gene therapy is to modify the genetic material of living cells for therapeutic purposes, and this involves the insertion of a functional gene into a cell to achieve a therapeutic effect. The retroviral vector produced using the nucleic acid vectors and the host cells described herein can be used to transfect target cells and induce the expression of the gene of potential therapeutic interest. The retroviral vector can therefore be used for the treatment of a mammalian subject, such as a human subject, afflicted with a disease including, but not limited to, hereditary pathologies, cancer, and certain viral infections.
    In one embodiment, the nucleic acid vector further comprises a transcription regulatory element. For example, any of the elements described herein may be operably linked to a promoter so that expression can be controlled. The promoters referred to herein may include promoters known, in whole or in part, which may be constitutively active or inducible, for example in the presence of a regulatory protein. In one embodiment, the nucleic acid vector further comprises a high efficiency promoter such as a CMV promoter. This promoter has the advantage of promoting a high level of expression of the elements encoded on the non-mammalian nucleic acid vector. In another embodiment, the CMV promoter comprises a sequence derived from the human cytomegalovirus strain AD169. This sequence is available under accession number Genome X17403, for example from base pairs 173731 to 174404.
    In one embodiment, the nucleic acid vector further comprises an insulator, such as a chromatin insulator. The term "insulator" refers to a genetic sequence that blocks the interaction between promoters and activators. In another embodiment, the insulator (as a chromatin insulator) is present between each of the retroviral nucleic acid sequences. This helps prevent promoter interference (i.e., when the promoter of a transcription unit influences the expression of an adjacent transcription unit) between adjacent retroviral nucleic acid sequences. It will be understood that if the insulators are present in the nucleic acid vector between each of the retroviral nucleic acid sequences, then these can be arranged as individual expression hybrids within the vector of the nucleic acid. nucleic acid. For example, each sequence encoding retroviral nucleic acid sequences has its own promoter and / or intron and / or polyA signal. In one embodiment, the chromatin insulator has a sequence identity of at least 90%, for example at least 95%, with the sequence of chicken HS4 isolate (Gallus gallus) (e.g. Genome U78775.2, base pairs 1 to 1205).
    In one embodiment, the nucleic acid vector further comprises a polyA signal. The use of a polyA signal has the advantage of protecting the mRNA from enzymatic degradation and of facilitating translation. In one embodiment, the polyA signal is obtained or derived from SV40, bovine growth hormone and / or human beta globin. In one embodiment, the polyA signal is derived from the early SV40 polyA signal (e.g., see Genome Entry No. EF579804.1, base pairs 2668 to 2538 from the minus strand). In one embodiment, the polyA signal is derived from the polyA signal of human beta globin (e.g., see Genome GU324922.1 entry, base pairs 3394 to 4162).
    In one embodiment, the nucleic acid vector further comprises an intron sequence. The use of an intron downstream of the activator / promoter region and upstream of the cDNA insert (i.e., transgene) is known to increase the expression rate of the insert. In another embodiment, the intron sequence is an intron sequence of human beta globin or intron II of rabbit beta globin. In one embodiment, the intron of human beta globin is derived from the sequence available under Genome No. KM504957.1 (eg, from base pairs 476 to 1393). In one embodiment, intron II of the rabbit beta globin is derived from the sequence available under Genome V00882.1 entry # (eg from base pairs 718 to 1290).
    In one embodiment, the nucleic acid vector further comprises a posttranscription regulatory element of the groundhog virus (WPRE). The presence of the WPRE has been shown to enhance expression and, as such, is likely to be beneficial in achieving high levels of expression. In another embodiment, the WPRE is derived from the sequence available at Genomic Entry No. J04514.1 (e.g., from base pairs 1093 to 1684).
    In one embodiment, the nucleic acid vector further comprises an internal ribosome entry site (IRES). An IRES is a structured RNA element that is usually found in the 5 'untranslated region upstream of the 5' cap (which is required for assembly of the initiation complex). IRES is recognized by translation initiation factors and allows independent translation of the cap. In another embodiment, IRES is derived from the encephalomyocarditis virus (EMCV) genome (eg see Genome Accession No. KF836387.1, base pairs 151 to 724).
    In one embodiment, the nucleic acid vector further comprises a multiple cloning site (MCS). MCS is a short segment of DNA within the nucleic acid vector that contains multiple restriction sites (eg 10, 15 or 20 sites). These sites are usually present only once within the nucleic acid vector to ensure that the endonuclease cleaves only at a site. This allows the retroviral genes to be easily inserted using the appropriate endonucleases (i.e., restriction enzymes). It will be understood by those skilled in the art that the hybrids may be arranged in any order within the nucleic acid vector. In an exemplary embodiment, the nucleic acid vector comprises the following insert: a retroviral nucleic acid sequence encoding the gag and pol proteins, a retroviral nucleic acid sequence encoding the env protein or a substitute function thereof (such as VSVg) and a retroviral nucleic acid sequence encoding the rev helper gene (such as an optimized codon rev sequence) or a gene analogous thereto or a functionally analogous system (ie that is, a BAC sequence retaining GagPol-Env-Rev ("BAC backbone"), such as: GagPol- (wild type) VSVg- (optimized codon) Rev-pSMARTBAC). In another embodiment, an insulator (such as a chromatin insulator) is present between each of the gagpol, env, and rev sequences. In another embodiment, a promoter is present between each of the gagpol, env, and rev sequences. In yet another embodiment, at least one copy of the transfer vector sequence (i.e. comprising the nucleic acid sequences that encode the genomic RNA of a retroviral vector particle) is present before the gagpol sequence.
    In one embodiment, the nucleic acid vector comprises the following insert: an insulator (such as a chromatin insulator), a promoter (such as a CMV promoter), an intron (such as a human beta globulin intron), a sequence retroviral nucleic acid encoding gag and pol proteins, a retroviral nucleic acid encoding RRE, a polyA signal (as a polyA signal of human beta globulin), an insulator (such as a chromatin insulator), a promoter (such as a CMV promoter) ), an intron (such as a human beta globulin intron), a retroviral nucleic acid sequence encoding the env protein or a functional substitute thereof (such as VSVg), a polyA signal (such as a beta globulin polyA signal) human), an insulator (such as a chromatin isolator), a promoter (such as a CMV promoter), a retroviral nucleic acid sequence encoding the rev helper gene or a gene analogous thereto, or a functionally analogous system, a signal polyA (as a polyA signal of human beta globulin), an insulator (such as a chromatin insulator), a promoter (such as a CMV promoter), an intron (such as a rabbit beta globulin intron), a polyA signal and a site multiple cloning. It will be appreciated that other sequences may be included with and / or within this insert.
    The nucleic acid sequences can be introduced into the nucleic acid vector sequentially. This allows selection after each integration to ensure that all the necessary nucleic acid sequences are successfully integrated into the nucleic acid vector. Alternatively, at least two or more nucleic acid sequences are introduced into the nucleic acid vector simultaneously.
    It will be understood that the additional genes described herein can be introduced into the nucleic acid vector by standard molecular cloning techniques known in the art, for example using restriction endonucleases and ligation techniques. In addition, the nucleic acid vector, in particular the BACs, PACs, fosmides and / or cosmids, can be introduced into bacterial host cells (such as E. coli cells, in particular E. coli strain DH10B). by standard techniques, such as electroporation.
    USES
    According to another aspect of the invention, the nucleic acid vector as defined herein is proposed for use in a method for producing retroviral vector particles. As described herein, the present invention provides multiple advantages for the use of the nucleic acid vectors described in transient transfection methods, primarily by reducing the 4-plasmid transfection system to a single acid vector. nucleic, which reduces the amount of material used.
    PROCESSES
    According to another aspect of the invention there is provided a method for producing a replication defective retroviral vector particle comprising: (a) introducing BAC as defined herein into a mammalian host cell culture ; and (b) culturing mammalian host cells under conditions to produce the defective retroviral vector particle in replication. The advantage of including all of the retroviral genes on a large nucleic acid vector is that they can be prepared in microbial cells (such as bacterial or yeast cells) first, which are easier to use and manipulate, before introducing them into mammalian cells in a single step.
    In one embodiment, the host cell is a mammalian cell. In another embodiment, the mammalian cell is selected from a HEK 293 cell, a HEK 6E cell, a CHO cell, a Jurkat cell, a KS62 cell, a PerC6 cell, a HeLa cell, a HOS cell, a cell H9, or a derivative or functional equivalent thereof. In yet another embodiment, the mammalian host cell is a HEK 293 cell or derived from a HEK 293 cell. These cell lines could be adherent cell lines (i.e., they grow into a monolayer attached to a surface) or adapted / non-adherent cell lines in suspension (i.e., they grow in suspension in a culture medium). In yet another embodiment, the HEK 293 cell is a HEK 293T cell or a HEK 6E cell. The term "HEK 293 cell" refers to the human embryonic kidney cell line 293 which is commonly used in biotechnology. In particular, HEK 293T cells are commonly used for the production of various retroviral vectors. Other examples of suitable commercially available cell lines include T REX ™ cell lines (Life Technologies).
    Host cells transduced using the methods defined herein may be used to produce a high titer of retroviral vector.
    References herein to the term "high titer" refers to an effective amount of a retroviral vector or particle that is capable of transducing a target cell, such as a patient cell. In one embodiment, a high titer is a titer exceeding 106 TU / ml without concentration (TU = transduction units). One skilled in the art will appreciate that the introduction of the nucleic acid vector into the host cell can be accomplished using appropriate methods known in the art, for example, lipid-mediated transfection (lipofection, microinjection cell fusion (as microcellular), electroporation, chemical-based transfection methods or microprojectile bombardment It will be understood that the choice of the method to be used for the introduction of the nucleic acid vector may depend on the In one embodiment, the introduction step (a) is carried out using lipofection, electroporation, or a chemical-based transfection method In another embodiment, the vector of the mammalian host cell is used. Nucleic acid is introduced into the host cell by lipofection.In an alternative embodiment, the nucleic acid vector is introduced into the host cell by a method. chemical-based transfection, such as calcium phosphate treatment. Calcium phosphate treatments are commercially available for example from Promega. Those skilled in the art will understand that the conditions used in the process described herein are dependent on the host cell used. Typical conditions, for example culture medium or temperature to be used, are well known in the art (see Kutner et al., (2009) Nature Protocols 4 (4): 495-505). In one embodiment, the culturing step (b) is performed by incubating the mammalian host cell under humid conditions. In another embodiment, the humidified conditions include incubating transfected cells at 37 ° C to 5% CO 2. In one embodiment, the culturing step (b) is performed using a culture medium selected from Dubelcco's Modified Eagle's Medium (DMEM) containing 10% (vol / vol) fetal bovine serum (FBS). or a serum-free UltraCULTURE ™ medium (Lonza, cat # 12-725F) or FreeStyle ™ expression medium (Thermo fisher, Cat # 12338 018).
    In one embodiment, the method further comprises isolating the defective retroviral vector particle in replication. For example, in one embodiment, isolation is achieved using a filter. In another embodiment, the filter is a membrane of low protein binding (for example a membrane of low protein binding of 0.22 μπι or a membrane of low protein binding of 0.45 μπι), such as membranes. Artificial polyvinylidene fluoride (PVDF) or polyethersulfone (PES).
    In one embodiment, replication defective retroviral vector particles are isolated less than 72 hours after the introduction step (a). In another embodiment, replication defective retrovirus particles are isolated between 48 and 72 hours after the introduction step (a), for example after 48, 49, 50, 51, 52, 53, 54 , 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71 or 72 hours.
    Once isolated, the retroviral vector particles can be concentrated for in vivo applications. Concentration methods include, for example, ultracentrifugation, precipitation or anion exchange chromatography. Ultracentrifugation is useful as a fast method for small-scale retroviral vector concentration. Alternatively, anion exchange chromatography (using, for example, Mustang Q anion exchange membrane cartridges) or precipitation (e.g. using PEG 6000) is particularly useful for processing large volumes of lentiviral vector supernatants.
    According to another aspect of the invention, there is provided a defective retroviral vector particle in replication obtained by the method as defined in this specification. The invention will now be described in more detail with the aid of the following non-limiting examples.
    EXAMPLES EXAMPLE 1 Hybrid Construction Guide
    Figure 1 shows a step-by-step guide for building BACpack-WTGP-277delU5 and BACpack-SYNGP-277delU5. With the compatible ends of an Xbal and Nhel digest, the lentiviral packaging genes were progressively loaded into the pSmart BAC vector. At the time of GagPol addition, 2 hybrids were made which contained either wild type GagPol (WTGP) or optimized codon GagPol (SYNGP). The nomenclature of BACpack-WTGP and BACpack-SYNGP was given to them respectively. The transfer cassette was then loaded on these two hybrids, generating BACpackWTGP-277delU5 and BACpackSYNGP-277delU5.
    EXAMPLE 2: Proof of Principle Experiment Using Hybrid BAC 106 HEK293T cells were seeded in a 6-well plate. The next day, the adhered cells were transfected using PEI according to the manufacturer's instructions. Cells were then transfected with either a total of 4 μg of wild-type lentiviral packaging hybrids (WT) consisting of pMDL.gp (GagPol), pMD.G (VSVg), pK-Rev (Rev) and pCCL. 277 (GFP transfer vector) or 2 μg BACpack (a single BAC hybrid containing GagPol, VSVg and Rev) plus 2 μg of the eGFP transfer vector on a separate plasmid. 48 hours after transfection, the supernatant was harvested, filtered through a 0.22 μm filter and stored at -80 ° C for a minimum of 4 hours. HEK293T cells were seeded for transduction at 105 cells per well in a 24-well plate. The following day, the viral supernatant was applied to the cells in serial Polybrene dilutions to a final concentration of 8 μg / ml. 3 days after transduction, the cells were harvested by trypsin treatment and analyzed at the level of GFP by FACS. The viral titer was calculated in transduction units (TU) / ml, calculated according to the following equation: (GFP positive cells / 100) χ dilution factor χ number of transduced cells.
    Viral titers were compared on the bar graph (Figure 2). All incubations were performed at 37 ° C and 5% CO2. The media used were DMEM supplemented with 10% FBS and 1 μg / ml doxycycline in the BACpak + transfer sample.
    Observations:
    In this example, the capacity of the BACpack hybrid, consisting of the GagPol, VSVg, and Rev expression cassettes, was compared to the standard 3-plasmid packaging system where GagPol, VSVg, and Rev are distributed separately. In both cases, the transfer vector was delivered together in a separate plasmid to complete the essential components for the viral vector.
    In this example, the BACpack plus transfer vector was able to achieve a viral titer of the unconcentrated supernatant of 2.2 ± 107 TU / ml, compared to a titer of 5 χ 107 TU / ml when using a system. of lentivirus to 4 separate plasmids. Although a lower titre was observed using BACpack, this analysis allowed a pre-optimization and a higher title can be obtained post-optimization. From this proof of principle analysis, it can be concluded that BACpack is able to package the transfer vector at a viral titre level comparable to that of the separate packaging plasmid system in transient transfection. EXAMPLE 3 Transient BACpack transfection in adherent HEK293T cells
    In order to confirm the ability of both BACpack-277delU5 hybrids to produce the lentiviral vector in a transient transfection system, the adherent cell line, HEK293T, routinely used to produce a lentiviral vector by transient transfection, was transfected with either the to 4 current packaging plasmids, either BACpackWTGP-277delU5 or BACpackSYNGP-277delU5. Both BACpack-277delU5 hybrids were either induced to evaluate whether gene expression could result in lentiviral vector production or left uninduced to test the efficiency of the Tet repressor system.
    The results in Figure 3 show the titer / ml (TU) / ml titre of the lentiviral vector supernatant harvested from each transfection condition. It can be seen from the titration results that cells transfected with either BACpackWTGP-277 from 1U5 or BACpackSYNGP-277delU5 and induced with 1 jug / ml doxycycline (+ Dox) produced lentiviral vector concentrations comparable to the 4 plasmid system. current. In addition, the uninduced conditions demonstrated a greatly reduced ability to produce the lentiviral vector over those induced, and although this production was greater than the untransfected control background, this can not be considered a disadvantage in a transitional system.
    These results suggest that the single BAC vector containing all of the packaging genes required for. lentiviral production could replace the current 4-plasmid system.
    It will be understood that the embodiments described herein can be applied to all aspects of the invention.
    权利要求:
    Claims (26)
    [1" id="c-fr-0001]
    1. Artificial bacterial chromosome (BAC), characterized in that said BAC comprises retroviral nucleic acid sequences encoding: the gag and pol proteins, and an env protein in which each of the retroviral nucleic acid sequences is arranged under the form of individual expression hybrids within the BAC.
    [2" id="c-fr-0002]
    The artificial bacterial chromosome according to claim 1, which further comprises nucleic acid sequences which encode the genomic RNA of a retroviral vector particle.
    [3" id="c-fr-0003]
    The bacterial artificial chromosome of claim 1 or claim 2, which further comprises the helper gene rev.
    [4" id="c-fr-0004]
    4. Artificial bacterial chromosome according to any one of claims 1 to 3, wherein the retroviral nucleic acid sequences are derived from a retrovirus selected from lentiviruses, alpha-retroviruses, gamma-retroviruses or foamy retroviruses.
    [5" id="c-fr-0005]
    The bacterial artificial chromosome according to claim 4, wherein the retroviral nucleic acid sequences are derived from a lentivirus selected from the group consisting of HIV-1, HIV-2, VIS, VIF, VAIE and Visna.
    [6" id="c-fr-0006]
    The artificial bacterial chromosome of claim 5, wherein the retroviral nucleic acid sequences are derived from HIV-1.
    [7" id="c-fr-0007]
    The bacterial artificial chromosome according to any one of claims 1 to 6, wherein the env protein or a functional substitute thereof is derived from the vesicular stomatitis virus.
    [8" id="c-fr-0008]
    The bacterial artificial chromosome according to any one of claims 1 to 7, which further comprises a transcriptional regulatory element.
    [9" id="c-fr-0009]
    The artificial bacterial chromosome of claim 8, wherein the transcriptional regulatory element is a CMV promoter.
    [10" id="c-fr-0010]
    The artificial bacterial chromosome according to any one of claims 1 to 9, which further comprises an insulator.
    [11" id="c-fr-0011]
    The bacterial artificial chromosome of claim 10, wherein an insulator is present between each of the retroviral nucleic acid sequences.
    [12" id="c-fr-0012]
    The bacterial artificial chromosome according to any one of claims 1 to 11, which further comprises one or more transgenes.
    [13" id="c-fr-0013]
    The artificial bacterial chromosome according to any one of claims 1 to 12, which further comprises an internal ribosome entry site (IRES).
    [14" id="c-fr-0014]
    The bacterial artificial chromosome according to any one of claims 1 to 13, which further comprises a polyA signal.
    [15" id="c-fr-0015]
    The artificial bacterial chromosome according to any one of claims 1 to 14, which further comprises an intron sequence.
    [16" id="c-fr-0016]
    The artificial bacterial chromosome according to any one of claims 1 to 15, which further comprises a multiple cloning site (MCS).
    [17" id="c-fr-0017]
    17. Artificial bacterial chromosome according to any one of claims 1 to 16 for use in a method for producing retroviral vector particles.
    [18" id="c-fr-0018]
    A method of producing a replication defective retroviral vector particle, comprising: (a) introducing the bacterial artificial chromosome according to any one of claims 1 to 16 into a mammalian host cell culture; and (b) culturing mammalian host cells under conditions to produce the defective retroviral vector particle in replication.
    [19" id="c-fr-0019]
    The method of claim 18, wherein the mammalian host cell is a HEK 293 cell.
    [20" id="c-fr-0020]
    The method of claim 18 or claim 19, wherein the introducing step (a) is performed using lipofection, electroporation or a chemically based transfection template, such as calcium phosphate treatment.
    [21" id="c-fr-0021]
    The method of any one of claims 18 to 20, wherein the culturing step (b) is performed by incubating the mammalian host cell under humid conditions.
    [22" id="c-fr-0022]
    The method of any one of claims 18 to 21, further comprising isolating the defective retroviral vector particle in replication.
    [23" id="c-fr-0023]
    The method of claim 22, wherein the isolation is performed using a filter, such as a membrane of low protein binding.
    [24" id="c-fr-0024]
    The method of claim 22 or claim 23, wherein the replication defective retroviral vector particles are isolated less than 72 hours after the introduction step (a).
    [25" id="c-fr-0025]
    The method of claim 24, wherein the replication defective retroviral vector particles are isolated between 48 and 72 hours after the introducing step (a).
    [26" id="c-fr-0026]
    26. Replication defective retroviral vector particle obtained by the method according to any one of claims 18 to 25.
    类似技术:
    公开号 | 公开日 | 专利标题
    FR3044017A1|2017-05-26|TRANSIENT TRANSFECTION METHOD FOR RETROVIRAL PRODUCTION
    FR3044016A1|2017-05-26|STABLE CELL LINES FOR RETROVIRAL PRODUCTION
    Sakuma et al.2012|Lentiviral vectors: basic to translational
    AU778698B2|2004-12-16|Method and means for producing high titer, safe, recombinant lentivirus vectors
    JP6878620B2|2021-05-26|Stable cell line for retrovirus production
    US9932597B2|2018-04-03|Vectors for transgene expression
    GB2538321A|2016-11-16|Artificial chromosome for retroviral production
    EP3455239B1|2021-04-07|Particle for the encapsidation of a genome engineering system
    US9840720B2|2017-12-12|Materials and methods relating to packaging cell lines
    EP3294756A1|2018-03-21|Retroviral particle comprising at least two encapsidated non-viral rnas
    GB2538324A|2016-11-16|Packaging cell line for retroviral production
    FR3036118B1|2019-07-12|RETROVIRAL PARTICLE COMPRISING AT LEAST TWO ENCAPSID NON-VIRAL RNA
    GB2544891A|2017-05-31|Transient transfection method for retroviral production
    FR3051196A1|2017-11-17|PARTICLE FOR THE ENCAPSIDATION OF A GENOME ENGINEERING SYSTEM
    同族专利:
    公开号 | 公开日
    AU2016359838B2|2020-08-06|
    CN108291211A|2018-07-17|
    RU2749717C2|2021-06-16|
    KR20180073624A|2018-07-02|
    DE102016122317A1|2017-05-24|
    KR102067352B1|2020-01-16|
    JP2019500030A|2019-01-10|
    FR3044017B1|2019-05-03|
    RU2018118964A3|2020-04-02|
    SA518391585B1|2020-10-26|
    US20200063144A1|2020-02-27|
    US20170145427A1|2017-05-25|
    US10450574B2|2019-10-22|
    AU2016359838A1|2018-05-24|
    WO2017089307A1|2017-06-01|
    IL259223D0|2018-07-31|
    RU2018118964A|2019-12-26|
    CA3006285A1|2017-06-01|
    EP3380605A1|2018-10-03|
    BR112018010639A2|2019-01-22|
    IT201600117287A1|2018-05-21|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US5593972A|1993-01-26|1997-01-14|The Wistar Institute|Genetic immunization|
    WO1995003400A1|1993-07-23|1995-02-02|Johns Hopkins University School Of Medicine|Recombinationally targeted cloning in yeast artificial chromosomes|
    RU2187301C2|1995-06-27|2002-08-20|Бавариан Нордик А/С|Capsule for cells producing viral particles, method of its preparing and using|
    EP0880595A1|1996-02-13|1998-12-02|Fred Hutchinson Cancer Research Center|10a1 retroviral packaging cells and uses thereof|
    FR2751223B1|1996-07-19|1998-12-04|Rhone Merieux|FELIN POLYNUCLEOTIDE VACCINE FORMULA|
    US6277621B1|1998-02-26|2001-08-21|Medigene, Inc.|Artificial chromosome constructs containing foreign nucleic acid sequences|
    DK1141315T3|1998-12-31|2008-05-19|Novartis Vaccines & Diagnostic|Modified HIV Env polypeptides|
    US6677155B1|1999-04-22|2004-01-13|The General Hospital Corporation|Triple hybrid amplicon vector systems to generate retroviral packaging lines|
    WO2000065077A1|1999-04-22|2000-11-02|The General Hospital Corporation|Triple hybrid amplicon vector systems to generate retroviral packaging lines|
    CA2371946A1|1999-04-29|2000-11-09|Aarhus University|Expression of heterologous genes from an ires translational cassette in retroviral vectors|
    WO2000075299A1|1999-06-07|2000-12-14|Cell Genesys, Inc.|Hybrid yeast-bacteria cloning system and uses thereof|
    JP4436024B2|1999-10-12|2010-03-24|アンスティテュ・パストゥール|Lentiviral triplex DNA, and vectors and recombinant cells containing lentiviral triplex DNA|
    US20060057553A1|2000-05-30|2006-03-16|Estuardo Aguilar-Cordova|Chimeric viral vectors for gene therapy|
    WO2002022663A2|2000-09-18|2002-03-21|Maxygen, Inc.|Stress resistant retroviruses|
    US6586251B2|2000-10-31|2003-07-01|Regeneron Pharmaceuticals, Inc.|Methods of modifying eukaryotic cells|
    US7214515B2|2001-01-05|2007-05-08|The General Hospital Corporation|Viral delivery system for infectious transfer of large genomic DNA inserts|
    DE10111433A1|2001-03-09|2002-09-19|Bundesrepublik Deutschland Let|Replication-competent molecular clones of porcine endogenous retrovirus class A and class B, derived from porcine and human cells|
    MXPA03010626A|2001-05-30|2004-12-06|Chromos Molecular Systems Inc|Chromosome-based platforms.|
    JP4598398B2|2002-02-01|2010-12-15|オックスフォードバイオメディカ（ユーケー）リミテッド|Virus vector|
    EP1495125B1|2002-04-10|2010-06-16|THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES|Vac-bac shuttle vector system|
    MXPA05005549A|2002-11-25|2005-08-16|Bavarian Nordic As|Recombinant poxvirus comprising at least two cowpox ati promoters.|
    MXPA06012511A|2004-04-28|2006-12-15|Univ Pennsylvania|Polyvalent viral vectors and a system for production thereof.|
    US20080226677A1|2004-05-06|2008-09-18|Yasuko Mori|Recombinant virus vector for gene transfer into lymphoid cells|
    EP1652932A1|2004-11-02|2006-05-03|GBF Gesellschaft für Biotechnologische Forschung mbH|Method for the generation of virus producing cell lines and cell lines|
    EP2088193B1|2004-11-24|2011-01-12|Anaeropharma Science Inc.|Novel shuttle vector|
    EP1817422A2|2004-11-24|2007-08-15|Nanovector Limited|Viral vectors|
    WO2008115199A2|2006-08-18|2008-09-25|The University Of North Carolina At Chapel Hill|Chimeric virus vaccines|
    GB0702695D0|2007-02-12|2007-03-21|Ark Therapeutics Ltd|Production of vectors|
    US8440461B2|2007-03-23|2013-05-14|Wisconsin Alumni Research Foundation|Reprogramming somatic cells using retroviral vectors comprising Oct-4 and Sox2 genes|
    WO2009146150A2|2008-04-04|2009-12-03|University Of Miami|Viral recombineering and uses thereof|
    ES2460947T3|2010-09-02|2014-05-16|Molmed Spa|Stable production of lentiviral vectors|
    US9273324B2|2010-12-05|2016-03-01|Andrew S. Belmont|Recombinant gene expression|
    WO2012170431A2|2011-06-06|2012-12-13|Bluebird Bio, Inc.|Improved geneswitch systems|
    GB201202516D0|2012-02-13|2012-03-28|Ucl Business Plc|Materials and methods relating to packaging cell lines|
    US20150224209A1|2012-09-14|2015-08-13|The Regents Of The University Of California|Lentiviral vector for stem cell gene therapy of sickle cell disease|
    EP3117004A4|2014-03-14|2017-12-06|University of Washington|Genomic insulator elements and uses thereof|
    GB2538324A|2015-05-15|2016-11-16|Glaxosmithkline Ip Dev Ltd|Packaging cell line for retroviral production|
    GB2538321A|2015-05-15|2016-11-16|Glaxosmithkline Ip Dev Ltd|Artificial chromosome for retroviral production|
    KR102058113B1|2015-11-23|2019-12-23|주식회사 엘지화학|Electrode with Improved Adhesion Property for Lithium Secondary Battery and Preparing Method therof|
    IT201600117326A1|2015-11-24|2018-05-21|Glaxosmithkline Ip Dev Ltd|Stable cell lines for retroviral production.|CN107624131A|2015-05-15|2018-01-23|韦克塔里斯公司|The retroviral particle of non-viral RNA comprising at least two capsidations|
    IT201600117326A1|2015-11-24|2018-05-21|Glaxosmithkline Ip Dev Ltd|Stable cell lines for retroviral production.|
    GB201706121D0|2017-04-18|2017-05-31|Glaxosmithkline Ip Dev Ltd|Stable cell lines for retroviral production|
    EP3696272A1|2017-12-22|2020-08-19|Oxford BioMedicaLimited|Retroviral vector|
    GB201816919D0|2018-10-17|2018-11-28|Glaxosmithkline Ip Dev Ltd|Adeno-associated viral vector producer cell lines|
    GB202004371D0|2020-03-26|2020-05-13|Glaxosmithkline Ip Dev Ltd|CAR constructs|
    GB202005096D0|2020-04-07|2020-05-20|Glaxosmithkline|Modified vectors for production of retrovirus|
    法律状态:
    2017-10-18| PLFP| Fee payment|Year of fee payment: 2 |
    2018-10-17| PLFP| Fee payment|Year of fee payment: 3 |
    2018-10-26| PLSC| Publication of the preliminary search report|Effective date: 20181026 |
    2019-10-29| PLFP| Fee payment|Year of fee payment: 4 |
    2020-10-23| PLFP| Fee payment|Year of fee payment: 5 |
    2021-10-20| PLFP| Fee payment|Year of fee payment: 6 |
    优先权:
    申请号 | 申请日 | 专利标题
    GBGB1520764.0A|GB201520764D0|2015-11-24|2015-11-24|Transient transfection method for retroviral production|
    GB15207640|2015-11-24|
    GB16093544|2016-05-26|
    GBGB1609354.4A|GB201609354D0|2016-05-26|2016-05-26|Transient transfection method for retroviral production|
    [返回顶部]